擅长

专注于膀胱癌的规范化治疗。对于非肌层浸润型膀胱癌，注重疾病的全程管理，降低患者的复发风险。对于肌层浸润性膀胱癌，注重扩大盆腔淋巴结清扫以及超扩大盆腔淋巴结清扫，延长患者的生存时间；遵循王忠教授提出的修复重建理念，为合适的患者重建新的膀胱及控尿（原位新膀胱）。

个人简介

周林，医学博士。2012年毕业于复旦大学获学士学位，2015年毕业于复旦大学附属中山医院获硕士学位，2018年毕业于复旦大学附属中山医院获博士学位。2019年入职上海交通大学医学院附属第九人民医院。以膀胱癌免疫治疗为研究方向，2019年入选上海市扬帆英才计划，主持上海市科委项目1项。科研上聚焦于膀胱癌免疫微环境，以小鼠原位膀胱癌模型、人体肿瘤组织芯片、公共大数据以及分子生物学技术为研究手段，深入研究膀胱癌关键分子及信号通路对肿瘤免疫微环境的驯化，从而促进膀胱癌的发生发展及耐药，为开发新的治疗靶点奠定基础。以第一作者先后在OncoImmunology，J Urol、J Am Coll Surg 等国际权威泌尿外科学和肿瘤学期刊发表SCI 论文5 篇；此外还以共同第一作者在Urol Oncol、World J Urol等国际知名杂志发表SCI 论文4 篇。1. Zhou L, Xu L, Chen L, et al. Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology. 2017 2017;6(4).2. Zhou L, Chang Y, Xu L, et al. The Presence of Vascular Mimicry Predicts High Risk of Clear Cell Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology. Aug 2016;196(2):335-342.3. Zhou L, Cao Y, Bian T, et al. Number of Renal Columns Invaded by Tumor: A Novel Parameter for Predicting Complexity and Outcomes of Off-Clamp Open Partial Nephrectomy. Journal of the American College of Surgeons. Aug 2015;221(2):539-U810.4. Zhou L, Guo J, Wang H, Wang G. The zhongshan score: a novel and simple anatomic classification system to predict perioperative outcomes of nephron-sparing surgery. Medicine. 2015-Feb 2015;94(5):e506-e506.5. Zhou L, Chang Y, Xu L, et al. Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. Oncotarget. Nov 15 2016;7(46):76214-76223.6. Li Y, Zhou L, Bian T, et al. The zero ischemia index (ZII): a novel criterion for predicting complexity and outcomes of off-clamp partial nephrectomy. World journal of urology. Jul 2017;35(7):1095-1102.7. Wang Z, Xie H, Zhou L, et al. CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget. Aug 9 2016;7(32):51525-51534.8. Chang Y, Xu L, Zhou L, et al. Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma. Oncotarget. Apr 2016;7(17):24527-24536.9. Chang Y, Zhou L, Xu L, et al. High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma. Urologic oncology. 2017-Sep-13 2017.

执业地点

• 1

  上海交通大学医学院附属第九人民医院

  无号